Azzalure, a local muscle relaxant developed for aesthetic use produced by Galderma and Ipsen, has received approval in Spain.

The Spanish Medicines and Healthcare products Agency approved the new treatment for the temporary improvement in the appearance of moderate to severe glabellar lines in adult men and women aged 65 years and under.

The approval was based on several clinical trials involving more than 2,600 patients, which confirmed the safety and efficacy of Azzalure.

The new treatment is adapted from Dysport (botulinum toxin type-A), which is already marketed by Ipsen for therapeutic indications.

Azzalure is commercially available in the UK, France, Germany and the Nordic countries.